Smith v. C.R. Bard, Inc.

730 F. Supp. 2d 783, 2010 U.S. Dist. LEXIS 81098, 2010 WL 3122793
CourtDistrict Court, M.D. Tennessee
DecidedAugust 9, 2010
Docket3-09-0139
StatusPublished
Cited by15 cases

This text of 730 F. Supp. 2d 783 (Smith v. C.R. Bard, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Smith v. C.R. Bard, Inc., 730 F. Supp. 2d 783, 2010 U.S. Dist. LEXIS 81098, 2010 WL 3122793 (M.D. Tenn. 2010).

Opinion

MEMORANDUM

WILLIAM J. HAYNES, JR., District Judge.

Plaintiff, Michael Smith, a Tennessee citizen, filed this action under 28 U.S.C. §§ 1331 and 1343 and under 28 U.S.C. § 1332, the federal diversity statute, against Defendant, C.R. Bard, Inc., a New Jersey corporation, asserting claims of retaliatory discharge under the False Claims Act, 31 U.S.C. § 3730(h), (“FCA”), the Tennessee Public Protection Act, Tenn. Code Ann. § 50-1-304, (“TPPA”), Tennessee common law, and the Tennessee False Claims Act, Tenn.Code Ann. § 4-18-105, (“TFCA”). The gravamen of Plaintiffs claims is that Defendant terminated him in retaliation for his internal complaint against the Defendant’s improper off-label promotion and sale of Tegress in men. Plaintiff alleges that he did not remain silent about the off-label marketing and complained on three occasions — on January 31, 2008, in a discussion with Gary Lickovitch, on March 10, 2008, in an email to Mark Downey, and on March 26, 2008, in an email to Geoff Gerks.

Before the Court is Defendant’s motion for summary judgment (Docket Entry No. 73) and Plaintiffs motion for partial summary judgment (Docket Entry No. 72). In his motion, Plaintiff contends that as a matter of law Plaintiff was terminated and did not resign.

In its motion, Defendant contends that Plaintiffs state law claims fail because: (1) Plaintiff cannot show that he engaged in protected activities because his complaints did not further a public good nor involve the exercise of a statutory or constitutional right; (2) Plaintiff cannot establish that he was terminated; (3) Plaintiff lacks *787 proof of the requisite causation under either the TPPA or common law; (4) Defendant had a legitimate, non-diseriminatory reason to determine that Plaintiff had effectively resigned and that Plaintiff cannot show that Defendant’s determination was pretextual; and ©Plaintiff did not properly raise a TFCA claim, that such claim was abandoned and that the TFCA claim fails for the same reasons as his FCA claim. As to Plaintiffs FCA claim, Defendant contends that: (1) Plaintiffs proof fails on a subjective good faith and objectively reasonable belief that Defendant was committing a fraud against the government; (2) Plaintiff cannot prove that he suffered an adverse employment action; (3) Plaintiff cannot prove any causal connection between protected activity and any adverse employment action; and (4) Defendant had a legitimate, non-discriminatory reason to determine that Plaintiff had effectively resigned and that Plaintiff cannot show that Defendant’s determination was pretextual.

For the reasons set forth below, the Court concludes that Defendant’s motion for summary judgment should be granted and Plaintiffs motion for partial summary judgment should be denied.

I. FINDINGS OF FACT 1

In 2000, Plaintiff began working for Bard Urological Division (“BUD”), a former division of Bard that later merged with Bard Medical Division in June 2009. Plaintiff was a Territory Manager (“TM”), assigned to the Nashville, Tennessee, territory that was part of the Southeast District. (Docket Entry No. 107, Plaintiffs response to Defendant’s Statement of Undisputed Facts at ¶¶ 3, 13). BUD divided the country into eight sales districts that were headed by a District Manager (“DM”). Id. at ¶ 10. The districts, in turn, were sub-divided into territories that were assigned to individual TMs who traveled throughout the territory in an effort to meet, educate, and sell BUD products to current and potential customers. Id. at ¶ 11. Each TM reported to a District Manager (“DM”), who was responsible for supporting, coaching, and evaluating the TM. Id. at ¶ 9. Plaintiff had three DMs: Chris Roman (2004-2006); Matt Lemay (2006-2007); and Ryan McKeon (2007-2008) during his last four years of employment. Id. at ¶ 14.

BUD offered products, services and education for the surgical treatment of prostate cancer, diseases and conditions of the urinary tract (including Endourological products for the treatment and management of kidney and other stones), female incontinence, and pelvic prolapse (including the Pelvic Floor category of products, which encompass synthetic and biological therapies used to repair female anatomy). Id. at ¶4. TMs sold these major product categories to physicians and hospitals until 2006. Id. at ¶ 6. The products for the treatment of female incontinence included Slings, a surgical therapy for the treatment of incontinence, and Bulking, nonsurgical injectable therapies designed to prevent and treat incontinence. Id. at ¶ 5.

*788 In January 2006, BUD divided its sales force into Women’s Health and Urology and Men’s Health. As a Women’s Health TM, Plaintiff began selling exclusively Pelvic Floor, Slings, and Bulking products. Id. at ¶¶ 7-8. From April 2005 to January 2007, among the Bulking products for Women’s Health, TMs sold Tegress, a synthetic injectable therapy for the treatment of stress urinary incontinence in women. Id. at ¶ 7. Tegress was approved by the Food & Drug Administration (“FDA”) for use in women. Id. at ¶ 77. Bard, however, did not seek FDA approval of Tegress for men. Id. at ¶ 78.

On or about December 19, 2006, BUD announced its cessation of Tegress sales effective January 31, 2007. Id. at ¶ 86. BUD’s decision to stop selling Tegress was because Tegress sales did not achieve company expectations and a new technique made surgical treatment options more effective at treating incontinence, making synthetic injectable therapies less attractive. Id. at ¶ 87. BUD instructed its sales force that after January 31, 2007, to return all Tegress samples and return or destroy all Tegress marketing materials in then-possession. Id. at ¶ 88. Plaintiff does not have any proof of BUD’s Tegress sales after January 31, 2007. Id. at ¶ 90.

During Plaintiffs final four years of employment from 2004-2007, among non-rookie TMs, Plaintiff ranked 40/43; 27/41; 22/36; and 35/40, respectively. Id. at ¶¶ 15, 18, 22, 26, 31. With “overall” rankings that included rookies and territories without an assigned TM, Plaintiff ranked 53/60, 30/60, 23/53, and 38/53 during this same time period. Id. at ¶¶ 16, 18, 22, 26, 31. In 2004 Plaintiff missed his quota in four of five product categories and finished under the overall total quota, earning a “Needs Improvement” rating of his overall performance. Id. at ¶¶ 19-20.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gray v. Ballad Health
E.D. Tennessee, 2022
Fakorede v. Mid-South Heart Center, P.C.
182 F. Supp. 3d 841 (W.D. Tennessee, 2016)
Epperson v. Resource Healthcare of America, Inc.
566 F. App'x 433 (Sixth Circuit, 2014)
Walls v. Tennessee CVS Pharmacy, LLC
21 F. Supp. 3d 889 (M.D. Tennessee, 2014)
Young v. United Parcel Service, Inc.
992 F. Supp. 2d 817 (M.D. Tennessee, 2014)
Levan v. Sears, Roebuck & Co.
984 F. Supp. 2d 855 (E.D. Tennessee, 2013)
Johnson v. Bellsouth Telecommunications, Inc.
512 F. App'x 566 (Sixth Circuit, 2013)
Hajizadeh v. Vanderbilt University
879 F. Supp. 2d 910 (M.D. Tennessee, 2012)
Nollner v. Southern Baptist Convention, Inc.
852 F. Supp. 2d 986 (M.D. Tennessee, 2012)
Reginald Worthy v. Michigan Bell Telephone Co
472 F. App'x 342 (Sixth Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
730 F. Supp. 2d 783, 2010 U.S. Dist. LEXIS 81098, 2010 WL 3122793, Counsel Stack Legal Research, https://law.counselstack.com/opinion/smith-v-cr-bard-inc-tnmd-2010.